MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 180 Publications

19 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

  • Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

    IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)		 Akt2 [1]
(Cell-free assay)		 Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 M3LvOGN6fG:2b4jpZ{BCe3OjeR?= Mm\lN{DPxE1? NGHKRXM4OiCq NUCzOm1HTE2VTx?= Mn3OTY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? NIrVZ|QzODV5MUC2PS=>
A431 MYfLbY5ie2ViQYPzZZk> NInGb5E2KM7:TR?= NHvYd5Q2KGh? NFzpfmhFVVOR M2nCTnN2eHC{ZYPz[ZMhfGinIIPp[45idGmwZzDv[kBCc3RiYX7kJGVzcw>? NGLSO|EzODV5MUC2PS=>
HepG2 MXTDfZRwfG:6aXOgRZN{[Xl? M1:ySVExKM7:TR?= M4\qN|I1KGh? NH2x[llFVVOR Mn3SV4Vve2m2aYrld{Bz\XOrc4ThcpQh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gd49z[W[nbnni NELYcWkzOTJyNUmyOS=>
Sk-Hep1 NH6zdZJEgXSxdH;4bYMhSXO|YYm= MUexNEDPxE1? MkX4NlQhcA>? MWLEUXNQ NHiwRZlU\W6|aYTpfoV{KHKnc3nzeIFvfCClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjJIVn\mWldDDv[kB{d3KjZnXubYI> MlqxNlEzODV7MkW=
OCUT1 cells harbored PIK3CA (H1047R+/+) NHrQbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnVbHNPOyEQvF2= NX;J[mJ4PSCm NGj2XnhFVVOR MorBTWM2OD1yLkG0JO69VQ>? MVmyNVI5QTJ4Nx?=
K1 cells harbored PIK3CA (E542K+/+) NX3abYJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PWNlMh|ryP MmHtOUBl Ml7MSG1UVw>? MXPJR|UxRTBwNUKg{txO NHHXbYYzOTJ6OUK2Oy=>
FTC133 cells harbored PTEN (allele deletion and R130+) MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:1eWNrOyEQvF2= NVTTUplQPSCm MoDvSG1UVw>? MlnnTWM2OD1yLkG4JO69VQ>? NX\hcW1[OjF{OEmyOlc>
C643 cells harbored HRAS (G13R+/−) MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF31U44{KM7:TR?= NFTXW4s2KGR? NHT6NlNFVVOR NEm5TVRKSzVyPUCuNlch|ryP MnvFNlEzQDl{Nke=
Hth7 cells harbored NRAS (Q61R+/−) NVjSVpFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\MTVMh|ryP M1TlWFUh\A>? NVnzZ5JzTE2VTx?= M2XxR2lEPTB;ND61JO69VQ>? MXGyNVI5QTJ4Nx?=
TPC1 cells harbored RET/PTC1 rearrangement NYX2d49uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKzJO69VQ>? MW[1JIQ> NITne4xFVVOR MYXJR|UxRTBwNUmg{txO M{fLPFIyOjh7Mk[3
Hth74 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT0Oow{KM7:TR?= M3HSNlUh\A>? NGHm[JhFVVOR MYPJR|UxRTJwMUmg{txO NX7J[3M1OjF{OEmyOlc>
KAT18 M1jlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PucFMh|ryP M1e0XlUh\A>? NWrpd4ZKTE2VTx?= NFjsZ|ZKSzVyPUSuOlIh|ryP Mn64NlEzQDl{Nke=
SW1736 M3TJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHYUHkyODBizszN M1;MNFUh\A>? NHT4W|JFVVOR MWrJR|UxRTR5LkW2JO69VQ>? NEPKVYEzOTJ6OUK2Oy=>
WRO NF7nZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7DR|N{OTByMDFOwG0> M3;seFUh\A>? MYLEUXNQ Mo\wTWM2OD5zMECwJO69VQ>? M3fqZlIyOjh7Mk[3
TAD2 NUXIbpJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;YNVAxOCEQvF2= MmG2OUBl NHHDfGZFVVOR Mny0TWM2OD5zMECwJO69VQ>? MX2yNVI5QTJ4Nx?=
LN229 M3;XNWFxd3C2b4Ppd{BCe3OjeR?= M12wclAvPSEQvF2= MmTiOlAhcA>? MnqxSG1UVw>? M{jEe2F2\22nboTzJIFxd3C2b3flcolkKGWoZnXjeJMhd2ZiZ3XmbZRqdmmk NH;jSo0zOjB3N{mxOC=>
T98G NIn2cVBCeG:ydH;zbZMhSXO|YYm= M1r1[lAvPSEQvF2= M4fCWVYxKGh? MmnpSG1UVw>? Mn7uRZVodWWwdIOgZZBweHSxZ3XubYMh\W[oZXP0d{Bw\iCpZX\peIlvcWJ? MkPQNlIxPTd7MUS=
HC11 NX[3N2lxTnWwY4Tpc44hSXO|YYm= NHTQb2EyOCEQvF2= NF[wdlgzPCCq MYLEUXNQ NVWzTW9XUW6qaXLpeJMh|rJvY3Hz[YlvKGGwZDDBSHJRKHO7boTo[ZNqew>? NHnYZY8zOjR{Nk[yNS=>
MOLT-4 NEHVWHhEgXSxdH;4bYMhSXO|YYm= MUixNEDPxE1? NFP4dJI1QCCq NV[yU3FRTE2VTx?= MWPJR|UxRTFwN,MAje69VQ>? MmP5NlI3OTR{NEO=
CEM-R NEPxW|FEgXSxdH;4bYMhSXO|YYm= MX[xNEDPxE1? NV;aWodYPDhiaB?= NYjLO3I5TE2VTx?= MXXJR|UxRTNwM,MAje69VQ>? MWOyNlYyPDJ2Mx?=
CEM-S NEXxNlNEgXSxdH;4bYMhSXO|YYm= NXLte41WOTBizszN NXfyXIJJPDhiaB?= M{X6VmROW09? MnjYTWM2OD13LkJihKnPxE1? Ml;qNlI3OTR{NEO=
MOLT-4 NIO5R3JHfW6ldHnvckBCe3OjeR?= MX[xNEDPxE1? M{nMRlI1KGh? MUfEUXNQ NULTZlF2SmyxY3vzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZTDv[kB1cGViY3XscEBkgWOuZR?= NF;nWWQzOjZzNEK0Ny=>
MOLT-4 NGD5eFZHfW6ldHnvckBCe3OjeR?= NUXZSIozPOLCid88US=> NUTsSJNXPCCq M{LDUWROW09? MUDJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFM1GvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> MX6yNlYyPDJ2Mx?=
CEM-R NYHCZpVFTnWwY4Tpc44hSXO|YYm= M4jNelTjiIoQvF2= MlvVOEBp NUm5[4U2TE2VTx?= NHPBeHNKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDOGEwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? NVvIfVBZOjJ4MUSyOFM>
CEM-S NFjDNFVHfW6ldHnvckBCe3OjeR?= NIjadYQ16oDLzszN M4jZOlQhcA>? NFq1e|lFVVOR MXrJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFNVGvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> MWCyNlYyPDJ2Mx?=
HepG2 cell NI\mNGdMcW6jc3WgRZN{[Xl? MYeyNEDPxE1? MmHGNlQhcA>? MVrEUXNQ MW\Ec5dvemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gRWtV MnLZNlM4QTd|MUm=
HepG2 cell NVP2[IZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\VN|Ah|ryP MXiyOEBp NEnadYZFVVOR NIC4O|BKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NUjaTFVPOjN5OUezNVk>
HepG2 cell MonDRZBweHSxc3nzJGF{e2G7 MmPCNlAh|ryP MUmyOEBp Ml;RSG1UVw>? MY\JcoR2[2W|IHPlcIwh[XCxcITvd4l{ MUKyN|c6PzNzOR?=
GEO MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe1NFAhdk1? NFHt[IY4OiCq M1S0NWROW09? NHvnW25KdmirYnn0d{Bk\WyuIHfyc5d1cA>? M4jX[VI1PThzMkOx
CNE-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKxNEDPxE1? NWLaSph{QTZiaB?= NEHrNZRFVVOR MkTZTWM2OD1{Lkm2JO69VQ>? MVqyOVM{Pjl{NR?=
CNE-2 M2eyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M360ZlExKM7:TR?= M4DKR|k3KGh? NFzWWGVFVVOR MlL5TWM2OD12LkWzJO69VQ>? M3X4elI2OzN4OUK1
HONE-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmxNEDPxE1? MUC5OkBp MXzEUXNQ NWjqZ5VTUUN3ME2zMlM4KM7:TR?= MWeyOVM{Pjl{NR?=
SUNE-1 NGP0cmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDJNndpOTBizszN NICxSFM6PiCq M{TnSWROW09? MnrOTWM2OD1yLkWyJO69VQ>? NEf0bVYzPTN|NkmyOS=>
CNE-2 NHntNGNHfW6ldHnvckBCe3OjeR?= MXKxNEDPxE1? NITRUZo1QCCq MXfEUXNQ NI[3VWhKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KEdz NVLHflI4OjV|M{[5NlU>
HONE-1 Ml:wSpVv[3Srb36gRZN{[Xl? NIX3UVQyOCEQvF2= MkTkOFghcA>? NYixZ3JwTE2VTx?= NVzjc3JMUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCJMR?= NFzvWZAzPTN|NkmyOS=>
NEC8 Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;6TFdKSzVyPUCuNFk3PTFizszN NULzSoNJW0GQR1XS
P12-ICHIKAWA M2rzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\UTWM2OD1yLkGxOlIh|ryP MVvTRW5ITVJ?
MDA-MB-175-VII NUnpRVFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMUO3N|gh|ryP M3j0XnNCVkeHUh?=
AsPC-1 NXLxZnRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TNUmlEPTB;MD6yNlEzOiEQvF2= MkC2V2FPT0WU
T47D MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGqzdnpKSzVyPUCuNlgzPSEQvF2= NFTSNW1USU6JRWK=
HH NYrObXBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT5TWM2OD1yLkOwNlg{KM7:TR?= M4TtOHNCVkeHUh?=
MOLT-16 MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXv[YpKSzVyPUCuN|A{OiEQvF2= M{DKRnNCVkeHUh?=
ES5 M4LX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PnfmlEPTB;MD6zOFQ2PSEQvF2= MWjTRW5ITVJ?
RS4-11 NYqyRpJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fiNWlEPTB;MD6zOFYyKM7:TR?= MoLXV2FPT0WU
KARPAS-45 MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TlTGlEPTB;MD6zO|MzOSEQvF2= NV7iPZFpW0GQR1XS
NCI-H720 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwM{e2O|kh|ryP MlrjV2FPT0WU
H9 NX\GSJNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTFTWM2OD1yLkO4PFg{KM7:TR?= MlnyV2FPT0WU
EFM-19 NE\lVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwNESwNUDPxE1? NFHodJFUSU6JRWK=
SBC-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjhT4VLUUN3ME2wMlQ1ODN3IN88US=> MWDTRW5ITVJ?
A4-Fuk NEmzXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;NTmRtUUN3ME2wMlQ3QDZ6IN88US=> NYHS[2N{W0GQR1XS
NCI-H1563 NIf2NY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{KwUWlEPTB;MD60PFE5QSEQvF2= NEfy[5hUSU6JRWK=
HCC1419 M1ToUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D1WWlEPTB;MD60PFg6OiEQvF2= MXjTRW5ITVJ?
H-EMC-SS M4nTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf5bWtzUUN3ME2wMlQ6QTN7IN88US=> MVrTRW5ITVJ?
BHT-101 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPWNHdnUUN3ME2wMlUzQTZzIN88US=> Ml;DV2FPT0WU
IGROV-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTBe5BKSzVyPUCuOVUzPDlizszN NEPBU41USU6JRWK=
HGC-27 MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHaU2RtUUN3ME2wMlU3Pzh|IN88US=> NFX5TVFUSU6JRWK=
MDA-MB-361 MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwNUe3OlEh|ryP MUDTRW5ITVJ?
KE-37 NYr6Z5VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTjTWM2OD1yLkW4NlYh|ryP NFiwbZNUSU6JRWK=
HCC70 NXnjNmNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m3eWlEPTB;MD61PVgzPyEQvF2= NV\LdXBSW0GQR1XS
LNCaP-Clone-FGC MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTkTWM2OD1yLk[xNFQ5KM7:TR?= MmrKV2FPT0WU
HAL-01 NEnqV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jPT2lEPTB;MD62NlE{KM7:TR?= MXLTRW5ITVJ?
HT M3;UcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6xTWM2OD1yLk[zNlM6KM7:TR?= Mn3VV2FPT0WU
MDA-MB-415 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vIb2lEPTB;MD62N|YzPiEQvF2= M1TJSXNCVkeHUh?=
NOS-1 MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fueGlEPTB;MD62N|czOyEQvF2= NXWzUXpwW0GQR1XS
DU-145 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwNkS3OFUh|ryP MVfTRW5ITVJ?
OCUB-M MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLYTWM2OD1yLkewPVY3KM7:TR?= MW\TRW5ITVJ?
VA-ES-BJ M2\CU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDCOJR4UUN3ME2wMlc{ODJ3IN88US=> NWDxPI5uW0GQR1XS
J-RT3-T3-5 NGXUfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX2yR2Q{UUN3ME2wMlc1PDB|IN88US=> M3WzdXNCVkeHUh?=
MOLT-4 Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz6TIt6UUN3ME2wMlgxPTh{IN88US=> NIfnbmNUSU6JRWK=
NB7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvoR5V3UUN3ME2wMlgzPDFzIN88US=> MU\TRW5ITVJ?
L-363 NUGwd3hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS4NmRKSzVyPUCuPFM1PDJizszN NGPUO4hUSU6JRWK=
NKM-1 M2\VOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwOE[yOVMh|ryP NUe3T4dxW0GQR1XS
HOP-92 NWruOWJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjoXZFKSzVyPUCuPFczOjNizszN MX;TRW5ITVJ?
OAW-42 NFjnOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwOEi3NkDPxE1? NInSbVVUSU6JRWK=
HuO9 NXzWd|VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwOUK3OVEh|ryP MmLHV2FPT0WU
MFE-280 M3XO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnmTWM2OD1yLkm2OFY2KM7:TR?= NG\qT5hUSU6JRWK=
EM-2 MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P3OWlEPTB;MD65O|k{QSEQvF2= M1Kzb3NCVkeHUh?=
NCI-H520 MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTQTWM2OD1yLkm4OVkzKM7:TR?= MonXV2FPT0WU
LB2241-RCC NUnZflNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3iTWM2OD1yLkm5O|M1KM7:TR?= MnzyV2FPT0WU
SK-NEP-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHBVHVKSzVyPUGuNVQ1QDVizszN NEDtfGdUSU6JRWK=
LXF-289 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC2TZMzUUN3ME2xMlE4OTV4IN88US=> NWDxW49MW0GQR1XS
EPLC-272H MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXVRXhKSzVyPUGuNVczPTZizszN MVTTRW5ITVJ?
COLO-684 NHvsbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTZSoZKSzVyPUGuNlM4OjVizszN NXTIWXV6W0GQR1XS
ES1 M1;HfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C5V2lEPTB;MT6yOFA3PSEQvF2= MWDTRW5ITVJ?
DOHH-2 NY\EV4kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjKTWM2OD1zLkK4NlA{KM7:TR?= NGfFUXBUSU6JRWK=
CTB-1 NXHvT29ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HrOWlEPTB;MT6yPFk6KM7:TR?= Mmr1V2FPT0WU
G-401 NXPCdZVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnSTWM2OD1zLkK5O|k2KM7:TR?= M2THcXNCVkeHUh?=
LoVo MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTxc4xjUUN3ME2xMlMzPTN2IN88US=> NXnsN5k5W0GQR1XS
Ramos-2G6-4C10 NXv4fGZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPa[m9KSzVyPUGuN|M4ODFizszN M1P1fHNCVkeHUh?=
MFM-223 NVvHSFlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnUXJRpUUN3ME2xMlM1PDZzIN88US=> M2fkWXNCVkeHUh?=
PA-1 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfSTWM2OD1zLkO1NlY2KM7:TR?= MYLTRW5ITVJ?
697 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXk[3VmUUN3ME2xMlM4PjF4IN88US=> MkPGV2FPT0WU
QIMR-WIL M3fQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD0bph7UUN3ME2xMlQ6OTF4IN88US=> NUfuO2huW0GQR1XS
HOS MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwNEm1OVgh|ryP NI\h[opUSU6JRWK=
DMS-273 NUPBc5B3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPzSoY1UUN3ME2xMlUyQTV7IN88US=> MlrVV2FPT0WU
ME-180 NWPDXlFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\FfZRkUUN3ME2xMlU3QDlzIN88US=> MlvFV2FPT0WU
HCC2218 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILSSm9KSzVyPUGuOlgzOjVizszN NH3yOpNUSU6JRWK=
CAL-54 NFT5WmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1yxc2lEPTB;MT63NVI1OiEQvF2= NG\Kc2NUSU6JRWK=
OMC-1 NEj5XGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwN{S2O|ch|ryP MkD5V2FPT0WU
COR-L105 NFfaTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnUU412UUN3ME2xMlc6PzN5IN88US=> M4LxU3NCVkeHUh?=
BV-173 M{TSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TOemlEPTB;MT64NVA4PCEQvF2= MVHTRW5ITVJ?
RKO NGjOVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXmVYxyUUN3ME2xMlg4OTBzIN88US=> M16xWnNCVkeHUh?=
SNU-387 MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFwOEi0NFYh|ryP MkCzV2FPT0WU
SW1088 NFTjSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmflTWM2OD1zLkm0OlA3KM7:TR?= M1vpOHNCVkeHUh?=
Hs-578-T NFnDSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\ZU2lEPTB;Mj6xNVQ{OyEQvF2= NGXnZYdUSU6JRWK=
OC-314 NH;mSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H0TWlEPTB;Mj6xOVA5PiEQvF2= NH\iWGJUSU6JRWK=
RMG-I NX3zPWJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvGTWM2OD1{LkG2N|k5KM7:TR?= NEjkbZVUSU6JRWK=
NCI-H1395 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PuOmlEPTB;Mj6xPFA6OSEQvF2= NFPY[4dUSU6JRWK=
GAMG MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTJwMkO4OFUh|ryP MVnTRW5ITVJ?
LB1047-RCC NUPVb2p3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TPTmlEPTB;Mj6yOFMyPyEQvF2= NX\sdWg3W0GQR1XS
MN-60 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Hne2lEPTB;Mj6yPVkzOyEQvF2= M3;IVHNCVkeHUh?=
OAW-28 Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJwMkm5OVEh|ryP NIjPbHNUSU6JRWK=
NCI-H2228 NIe1eo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;ubohtUUN3ME2yMlMyPTV{IN88US=> NU\PV2ZzW0GQR1XS
ABC-1 NVPMOFRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom4TWM2OD1{LkOzNlU{KM7:TR?= NVfKd3VNW0GQR1XS
LS-513 NFfCVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm4SXhvUUN3ME2yMlM{PDh2IN88US=> M4fZcHNCVkeHUh?=
KS-1 NV:0VpdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fOfGlEPTB;Mj6zPFE6OSEQvF2= M33tdXNCVkeHUh?=
NB69 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfpXYR2UUN3ME2yMlM5QTh|IN88US=> MW\TRW5ITVJ?
VM-CUB-1 NIjUUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvNWWRKSzVyPUKuN|kxQDNizszN NWLDbGNtW0GQR1XS
D-423MG M{C3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDzUW1KSzVyPUKuOFExPDRizszN NIWwbFJUSU6JRWK=
EW-18 M3fhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3rbnpKSzVyPUKuOFE6OzlizszN M4PXUXNCVkeHUh?=
YH-13 NWPaWFBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJwNE[xOVMh|ryP MnnEV2FPT0WU
T-24 NWjSSGpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLhOZJvUUN3ME2yMlQ4QDhzIN88US=> NXLPO5U6W0GQR1XS
ES8 M2jXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPSTWM2OD1{LkS5Nlg4KM7:TR?= NVW2UnVYW0GQR1XS
ES3 M121VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi1e5BRUUN3ME2yMlQ6PzV7IN88US=> M{\tWnNCVkeHUh?=
RXF393 NYHDVpRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TRRWlEPTB;Mj62NFQ5PyEQvF2= Mo\NV2FPT0WU
RPMI-8226 M2L2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJwNkK5OVMh|ryP MX\TRW5ITVJ?
AGS MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfDTWM2OD1{LkeyNVM4KM7:TR?= NWq0UXM4W0GQR1XS
HCC1395 M4j5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPnVYVUUUN3ME2yMlc2OTh5IN88US=> M1jrcHNCVkeHUh?=
MV-4-11 NHux[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LIc2lEPTB;Mj63OVI3PiEQvF2= MYnTRW5ITVJ?
A204 NHXOcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXHTWM2OD1{LkizPFczKM7:TR?= NVTXRYZyW0GQR1XS
MCF7 MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDseWx1UUN3ME2yMlg3OTF5IN88US=> NH7WVJBUSU6JRWK=
SNU-423 M2LObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\aXGlEPTB;Mj64PVI1OiEQvF2= MV3TRW5ITVJ?
NCI-H1048 NVvVcJNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr2V4I6UUN3ME2yMlk3QDZ3IN88US=> MoG1V2FPT0WU
GR-ST MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnX5TWM2OD1|LkC0OlEyKM7:TR?= MnHyV2FPT0WU
EoL-1- NVLWRpUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH5bFlKSzVyPUOuNFcxPThizszN NVvyZYFHW0GQR1XS
HuH-7 M4fQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTNwMEm0OlQh|ryP Mmf3V2FPT0WU
OS-RC-2 NUi4fIxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;RTWM2OD1|LkGxNVkh|ryP MUfTRW5ITVJ?
EW-3 Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET6ZVlKSzVyPUOuNVk2OjlizszN MYHTRW5ITVJ?
NCI-H747 NGW5dZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV62Z4dRUUN3ME2zMlIxPjl2IN88US=> NGK3VpZUSU6JRWK=
EW-16 M2e0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XMTmlEPTB;Mz6yNVg4QSEQvF2= M1[yWnNCVkeHUh?=
DOK NYnCRY5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTNwMkK4OVkh|ryP M2fQVXNCVkeHUh?=
HCC2157 NHvXfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNwM{ixO|kh|ryP MnPDV2FPT0WU
OVCAR-3 M{nyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33tUmlEPTB;Mz60NFc5PiEQvF2= NYrmS5d3W0GQR1XS
NCI-H1623 MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHSTWM2OD1|LkSxNlI1KM7:TR?= NWnaUWxKW0GQR1XS
H4 M4rxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvwTWM2OD1|LkS1OlI3KM7:TR?= MmrwV2FPT0WU
SW1710 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7FTWM2OD1|LkS2Olc5KM7:TR?= NVGzW2JDW0GQR1XS
RT-112 M2[5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHSxW|NKSzVyPUOuOVI{QDhizszN Mln5V2FPT0WU
DMS-114 MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml63TWM2OD1|Lk[yNlc5KM7:TR?= MnjEV2FPT0WU
AN3-CA MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrKNoJKSzVyPUOuOlI1PTZizszN NWH5e3B5W0GQR1XS
KNS-62 NYrwOm83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XRcmlEPTB;Mz62N|M{QCEQvF2= NILQSJNUSU6JRWK=
SJRH30 NUP6[WF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fhRWlEPTB;Mz62PVEzOiEQvF2= MlLSV2FPT0WU
G-402 NETNO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDxTWM2OD1|LkewO|EyKM7:TR?= NGD5ZXhUSU6JRWK=
MHH-PREB-1 NXn6NnUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTNwN{KwN|gh|ryP MmLkV2FPT0WU
P30-OHK MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTNwOEC5O|Yh|ryP MljrV2FPT0WU
RVH-421 M{LNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vEZWlEPTB;Mz64NVc5QCEQvF2= MVrTRW5ITVJ?
LU-134-A NWPnR5BLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MortTWM2OD1|Lki4OFI5KM7:TR?= MWfTRW5ITVJ?
ECC10 NVL2Vo5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvKVIVKSzVyPUOuPVM3OjJizszN NV3CU4JGW0GQR1XS
TGW MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTRwMEKzNFUh|ryP MX7TRW5ITVJ?
MLMA MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rqNGlEPTB;ND6wNlk3PiEQvF2= NV65PIpnW0GQR1XS
SCC-25 NWnYZVRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnwTWM2OD12LkC2OVY3KM7:TR?= MYXTRW5ITVJ?
TYK-nu NYfzPW9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2flTWlEPTB;ND6wPVU{PCEQvF2= MmTIV2FPT0WU
LAMA-84 NVv6XItMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTRwMUSxPVEh|ryP NH\hW5RUSU6JRWK=
Calu-3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrFfZdGUUN3ME20MlI1PDF4IN88US=> NWi2PZFwW0GQR1XS
NCI-H460 Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYruNZVpUUN3ME20MlI3PDR|IN88US=> NHfWOIdUSU6JRWK=
EGI-1 MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;VTWM2OD12LkO3O|c5KM7:TR?= NG\qbHNUSU6JRWK=
NCI-H292 NEDIXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XrcmlEPTB;ND6zPFE1PiEQvF2= M3r0RnNCVkeHUh?=
HCE-T MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPiPFRsUUN3ME20MlQyPTd7IN88US=> MYrTRW5ITVJ?
EW-11 NGXXW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHxdYJKSzVyPUSuOFE5OzhizszN NGDISXNUSU6JRWK=
ATN-1 NFKy[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[4PGlEPTB;ND60OFMxPCEQvF2= MlzLV2FPT0WU
NB5 NVnqe5hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfwTWM2OD12LkWzOlk4KM7:TR?= M3\vd3NCVkeHUh?=
KLE M{XTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTRwN{CxPVgh|ryP NEPpdJFUSU6JRWK=
CAL-39 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Tt[GlEPTB;ND63NlE1PiEQvF2= NISxOpRUSU6JRWK=
TI-73 NWPHPHZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTRwOEC2NFkh|ryP MV\TRW5ITVJ?
HO-1-N-1 MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnyxTWM2OD12Lkm0NkDPxE1? NUizcnBrW0GQR1XS
786-0 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTRwOUS2O|Mh|ryP MmTIV2FPT0WU
SK-N-DZ NGj1cI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn5TWM2OD12Lkm2NVQzKM7:TR?= NVnse2RjW0GQR1XS
NCI-H446 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TkVGlEPTB;NT6yNFAxQSEQvF2= M361UHNCVkeHUh?=
ETK-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO0V21KSzVyPUWuNlEyPjVizszN M1uyNHNCVkeHUh?=
BT-20 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS3SYhKSzVyPUWuNlE{PTNizszN NV7XXItUW0GQR1XS
MEL-HO M165cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTVwM{ezN|Yh|ryP M2e0O3NCVkeHUh?=
CAL-27 NHrOSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fMO2lEPTB;NT60OlM{QSEQvF2= NEHPSVBUSU6JRWK=
SW872 MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTVwNUm0Nlgh|ryP NXXMTY1jW0GQR1XS
RPMI-2650 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;nSmlEPTB;NT62OlE6QSEQvF2= NGrnSnJUSU6JRWK=
PFSK-1 NH3BbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET6d|JKSzVyPUWuO|I4OzJizszN MYPTRW5ITVJ?
SF295 M3X1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH20RnNKSzVyPUWuPFA3OzNizszN NWXVbFh{W0GQR1XS
Becker NED3UJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUmxXVdnUUN3ME21Mlg3PDd{IN88US=> MUDTRW5ITVJ?
Saos-2 MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTVwOE[1N{DPxE1? NXywbIlrW0GQR1XS
SK-OV-3 NWTuU3huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnRTWM2OD13Lkm5PFE3KM7:TR?= NFzTTFdUSU6JRWK=
VMRC-RCZ M2LBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vIU2lEPTB;Nj6wPFc4OyEQvF2= MoLZV2FPT0WU
EW-22 M1jhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTZwMUm2OFkh|ryP MlTTV2FPT0WU
BT-474 MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nmOWlEPTB;Nj6yN|Mh|ryP NF;ubm1USU6JRWK=
BFTC-909 M1[2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTZwM{CzOFUh|ryP MX3TRW5ITVJ?
NB12 M3;MUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq5[FR{UUN3ME22MlM6ODdzIN88US=> M2XXeHNCVkeHUh?=
D-263MG M3rrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\DTWM2OD14LkS1NVY6KM7:TR?= NVHpeoh[W0GQR1XS
SNB75 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnGVJhXUUN3ME22MlYxOTR|IN88US=> NWXsUVBrW0GQR1XS
A704 NHvKZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nIdmlEPTB;Nj62N|A3KM7:TR?= MVjTRW5ITVJ?
NCI-H1693 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq4e2tKSzVyPU[uOlM3ODRizszN M4PMZXNCVkeHUh?=
LN-405 M1zZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPBSY9wUUN3ME22Mlc6Pjd{IN88US=> M1jXRnNCVkeHUh?=
CHL-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m2RWlEPTB;Nj64NFA4QSEQvF2= Ml;xV2FPT0WU
A498 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zkUWlEPTB;Nj64NVk3OSEQvF2= NGfieZlUSU6JRWK=
TE-12 NYC5fGU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHvTWM2OD14LkizPFE4KM7:TR?= M1;2[nNCVkeHUh?=
TE-6 M17wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HtR2lEPTB;Nj65N|A{QCEQvF2= MkLGV2FPT0WU
AU565 NEfwcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHlTWg{UUN3ME22Mlk3QTV5IN88US=> NWG4bXFUW0GQR1XS
RD NFfXNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;5emlEPTB;Nj65PFI5PCEQvF2= NVfyVmZsW0GQR1XS
SW1463 M4m4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn25TWM2OD15LkGxNVY5KM7:TR?= NF7WfXBUSU6JRWK=
LU-99A NFHOOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rCOGlEPTB;Nz6xOFMzOiEQvF2= NF:0enVUSU6JRWK=
NCI-H28 NWHUdGNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TFOmlEPTB;Nz6yPVI1KM7:TR?= MXzTRW5ITVJ?
MC-IXC M3XGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfpTWM2OD15LkS4OVc3KM7:TR?= MVTTRW5ITVJ?
GP5d MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17vR2lEPTB;Nz60PFc3PCEQvF2= NF3iNZRUSU6JRWK=
GB-1 NHe4dGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTdwNUS4NFQh|ryP M3nNfXNCVkeHUh?=
CAL-33 Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TK[GlEPTB;Nz62OlI{OyEQvF2= Mn75V2FPT0WU
MSTO-211H M3mxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvpTWM2OD15Lk[3N|M3KM7:TR?= Mm\2V2FPT0WU
TE-5 NYq2NXZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT0UYFQUUN3ME23Mlc6OzN2IN88US=> MmTtV2FPT0WU
D-566MG Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRThwMES0Nlkh|ryP M4PE[HNCVkeHUh?=
JVM-3 MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;uPGlEPTB;OD6xOVI3QCEQvF2= M3f5RnNCVkeHUh?=
T98G NWTDNnV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHrfm51UUN3ME24MlE5ODZ5IN88US=> M{PxPHNCVkeHUh?=
HCC1954 NGW3cGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f4NWlEPTB;OD60OVExPCEQvF2= M{HIcHNCVkeHUh?=
SF126 M2KxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37rcGlEPTB;OD60OVk{PiEQvF2= NFLOWotUSU6JRWK=
LB996-RCC M1jjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrMNYZKSzVyPUiuOVMzPTdizszN MXvTRW5ITVJ?
SKG-IIIa M{LJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP3fFhbUUN3ME24MlY{ODZ7IN88US=> NGC0[XJUSU6JRWK=
NCI-SNU-1 NHu1NVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDrTWM2OD16Lk[0OlQ{KM7:TR?= MoKzV2FPT0WU
LB771-HNC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm3WpRKSzVyPUiuOlQ3QTZizszN MXvTRW5ITVJ?
SCC-4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPnSnFKSzVyPUiuOlgzOTlizszN NUTLc3pFW0GQR1XS
CAMA-1 M4Dtb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXFXHpKSzVyPUiuO|cyPDZizszN MU\TRW5ITVJ?
D-502MG NGHQWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvVTWM2OD16Lke4OlI6KM7:TR?= M3i5bXNCVkeHUh?=
ESS-1 MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\xTWM2OD16Lki4O|A1KM7:TR?= M173dXNCVkeHUh?=
HEC-1 NXXFbYcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRThwOEm4OlYh|ryP NHHjZmZUSU6JRWK=
NB10 MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVGy[pR3UUN3ME25MlAzOjJ2IN88US=> NFvMcHhUSU6JRWK=
8505C MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\6O2lEPTB;OT6wOFI{OiEQvF2= NVfxWWhxW0GQR1XS
EFO-27 NIDFc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTlwMU[0NVIh|ryP M164TXNCVkeHUh?=
HN Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTlwMU[2Nlgh|ryP NUP0V|lDW0GQR1XS
DSH1 NIjNcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7vTWM2OD17LkKwPFch|ryP M4nIS3NCVkeHUh?=
NBsusSR M{XlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTlwMke0NFIh|ryP NVSxW2lHW0GQR1XS
LS-123 MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTlwM{G3OlEh|ryP M2WzOHNCVkeHUh?=
SHP-77 NYr0Vlg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13jSmlEPTB;OT6zPVk{PSEQvF2= MnH3V2FPT0WU
ACN NGDwSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPNUmVKSzVyPUmuOVMzPzdizszN MnHNV2FPT0WU
U251 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonUTWM2OD17Lk[1OVQ1KM7:TR?= MlW1V2FPT0WU
A431 NXzST|J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zWSmlEPTB;OT64NFI{QCEQvF2= MYjTRW5ITVJ?
5637 NEG0flNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzmTWM2OD17Lki0PVg1KM7:TR?= NXvTSJRYW0GQR1XS
MDA-MB-157 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLDTWM2OD17LkmyPFc5KM7:TR?= M4HVR3NCVkeHUh?=
A101D MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTlwOUm5O|Qh|ryP NH3BUmlUSU6JRWK=
YKG-1 M1m1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ftOGlEPTB;MUCuNlAxPiEQvF2= NVjwWm0yW0GQR1XS
LAN-6 NETuOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDQfVI4UUN3ME2xNE4zOTZ2IN88US=> MYjTRW5ITVJ?
OVCAR-5 NHSxdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFyLkK0N|Mh|ryP NW\D[FNUW0GQR1XS
A549 NEjtS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvtTWM2OD1zMD6zPVc{KM7:TR?= NXjB[Wt2W0GQR1XS
no-11 NHfmdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4CxdmlEPTB;MUCuOFM2OyEQvF2= NF2zUXNUSU6JRWK=
SF539 NITIfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[0NlhKSzVyPUGwMlkxPDFizszN NInadplUSU6JRWK=
A388 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFzLkO4PVch|ryP NEnqNIdUSU6JRWK=
DEL NGLJO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPsTWM2OD1zMT60NlQh|ryP M4PtRnNCVkeHUh?=
SW954 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFzLkS2Olgh|ryP MWPTRW5ITVJ?
TK10 NGDFW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjjOYRKSzVyPUGxMlUzPzFizszN MWfTRW5ITVJ?
SW756 NEDNW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PmcGlEPTB;MUGuOVI6PCEQvF2= MWrTRW5ITVJ?
PC-3 M3HrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFzLkW3OlQh|ryP M2mzRnNCVkeHUh?=
ONS-76 NHvE[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFzLk[zOkDPxE1? NE\mWnBUSU6JRWK=
A427 NWLIblRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnUTWM2OD1zMT63NFk{KM7:TR?= Ml7KV2FPT0WU
MEG-01 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nQfGlEPTB;MUGuO|UxQSEQvF2= M37rTHNCVkeHUh?=
BB30-HNC NF;McVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm3NYhIUUN3ME2xNU44QTh{IN88US=> MXnTRW5ITVJ?
NCI-H1299 NGX3eJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG3TWM2OD1zMT64NFk{KM7:TR?= NVfSRVJ6W0GQR1XS
GCT M{\wdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TzUWlEPTB;MUGuPFIzQCEQvF2= M4LhTXNCVkeHUh?=
D-247MG NWrUSpNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3xRmFsUUN3ME2xNU46PjZ|IN88US=> M3PmTnNCVkeHUh?=
CFPAC-1 NH7wO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFzLkm3PFIh|ryP M{n1UnNCVkeHUh?=
EKVX M2X4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLFTWM2OD1zMj6wN|E{KM7:TR?= MX\TRW5ITVJ?
CAL-51 NIPJdGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm3NXQzUUN3ME2xNk4xPzF4IN88US=> MlTtV2FPT0WU
BB49-HNC NWXIUIxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H2W2lEPTB;MUKuNVE4PyEQvF2= NFP0RlRUSU6JRWK=
RPMI-7951 NXjX[mNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[0RWRlUUN3ME2xNk4yQDV2IN88US=> NHHWcm9USU6JRWK=
RH-1 MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF{LkKxPFQh|ryP Mkn5V2FPT0WU
BCPAP MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG4R|FKSzVyPUGyMlQ4PDlizszN MVjTRW5ITVJ?
GCIY NW\1emxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3roT2lEPTB;MUKuOVIxQSEQvF2= Mlj1V2FPT0WU
KNS-81-FD MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX1TWM2OD1zMj61PFY6KM7:TR?= NYjieIV5W0GQR1XS
KYSE-140 NX3XeVExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz5VWtKSzVyPUGyMlg2QTVizszN MnjLV2FPT0WU
Ca-Ski M3TibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfSb|JKSzVyPUGyMlkxPDFizszN MmT3V2FPT0WU
TGBC1TKB M324PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF{LkmxNVUh|ryP MoP6V2FPT0WU
HCC1187 NVjiTVFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P1UGlEPTB;MUOuNVkyOiEQvF2= MYLTRW5ITVJ?
SJSA-1 M1H1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF|LkKzNlch|ryP M4\QXnNCVkeHUh?=
CTV-1 M2PERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDCdWVyUUN3ME2xN{4{PDVizszN M1rhb3NCVkeHUh?=
WM-115 MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF|Lk[0PFMh|ryP NH7qeoRUSU6JRWK=
CHP-212 M{HGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrKTWM2OD1zMz65O|M6KM7:TR?= Mn3BV2FPT0WU
SCC-15 NFjmRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF|Lkm3O|Uh|ryP MmnvV2FPT0WU
BPH-1 NVK4R4lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF2LkG2OlQh|ryP NGXWNWNUSU6JRWK=
SW780 NVW4dmIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2noeWlEPTB;MUSuOVAzPSEQvF2= MV\TRW5ITVJ?
NCI-H2291 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknyTWM2OD1zND61PFc5KM7:TR?= NH;4OVBUSU6JRWK=
JEG-3 MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTtTWM2OD1zND62N|I3KM7:TR?= NGfxOVVUSU6JRWK=
CAL-120 M1HCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PWNmlEPTB;MUSuO|AzPyEQvF2= MW\TRW5ITVJ?
NCI-H23 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;STWM2OD1zND63PVk4KM7:TR?= NUPWbWtqW0GQR1XS
MS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUiwbll3UUN3ME2xOE46PjFzIN88US=> NGjsPVZUSU6JRWK=
PC-14 NF\YPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;INpFKSzVyPUG0Mlk3PTRizszN NWLD[oFYW0GQR1XS
D-283MED MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm4UGNKSzVyPUG1MlAyOTFizszN NFe0O|NUSU6JRWK=
OE19 MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrIRVNRUUN3ME2xOU4yPTRzIN88US=> NILLdHdUSU6JRWK=
CAS-1 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jRcGlEPTB;MUWuOFE5PCEQvF2= MkjyV2FPT0WU
NCI-H727 NVPGeWE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF3LkSyNlEh|ryP MnnEV2FPT0WU
SiHa MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\5[mlEPTB;MUWuO|U6PCEQvF2= MUfTRW5ITVJ?
BFTC-905 NX;Y[FZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj4TohKSzVyPUG1Mlc3QTRizszN NVTRdXh6W0GQR1XS
MDA-MB-453 NH7PcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF4LkG2OFIh|ryP NXu4V49{W0GQR1XS
HuP-T3 NUHafmtvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnztTWM2OD1zNj62N|c{KM7:TR?= M1HsTXNCVkeHUh?=
SK-LU-1 M2rDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmqzTWM2OD1zNj62PVU3KM7:TR?= NVzpfG9lW0GQR1XS
Detroit562 NE[wXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\xUXZKSzVyPUG2Mlc{OThizszN MXjTRW5ITVJ?
HCC1569 M{HWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWSybmFUUUN3ME2xOk45OzN5IN88US=> M4LkeXNCVkeHUh?=
SK-MES-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF4Lki0NVkh|ryP MVfTRW5ITVJ?
BB65-RCC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF5LkC0O|kh|ryP MnnVV2FPT0WU
LOXIMVI NWG5cVN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rhRWlEPTB;MUeuNFcxPyEQvF2= M1q5S3NCVkeHUh?=
SW1783 NGnwNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjaWIFMUUN3ME2xO{4yOjhizszN Mlv4V2FPT0WU
NH-12 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv3TnIyUUN3ME2xO{4{OzB|IN88US=> MYrTRW5ITVJ?
UACC-257 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrhWWRKSzVyPUG3MlU2OTJizszN M3;UPHNCVkeHUh?=
KOSC-2 NU\ibXExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W1[2lEPTB;MUeuOlc2PyEQvF2= MX7TRW5ITVJ?
KG-1 MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTHVWhKSzVyPUG3MlY6OzdizszN MoW2V2FPT0WU
M059J NEjadWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XsfWlEPTB;MUeuO|A{KM7:TR?= M3T4VHNCVkeHUh?=
MHH-NB-11 NGjVOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHUNmZKSzVyPUG3Mlk3PzNizszN NYm2cpN7W0GQR1XS
EW-1 Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK3TWM2OD1zOD6xN|gzKM7:TR?= M3\UVHNCVkeHUh?=
CAL-85-1 NVPZSZcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDabolKSzVyPUG4MlI{PTdizszN MnLxV2FPT0WU
639-V M2[1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16yNmlEPTB;MUiuN|M2PCEQvF2= MVLTRW5ITVJ?
C32 M1zkfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF6LkS3Nlch|ryP NEnaPFJUSU6JRWK=
KM-H2 NEDoUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3KyPWlEPTB;MUiuOVI{OiEQvF2= NWr4XIprW0GQR1XS
A253 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInyc4VKSzVyPUG4MlczQDZizszN MYTTRW5ITVJ?
NCI-N87 NIfRU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ntPWlEPTB;MUiuPVAxQCEQvF2= MW\TRW5ITVJ?
8-MG-BA NXnhTWtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfGSWxtUUN3ME2xPU4xPjR4IN88US=> M2WxOHNCVkeHUh?=
GI-ME-N NXTOZ4IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUniT3I5UUN3ME2xPU4yPTR4IN88US=> MWjTRW5ITVJ?
8305C NUKzS41qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DZd2lEPTB;MUmuNlI5PiEQvF2= NYfnT2V7W0GQR1XS
TE-8 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nnTWlEPTB;MUmuN|AzPCEQvF2= MkDwV2FPT0WU
KYSE-270 MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjPVYd5UUN3ME2yNE4xOjF5IN88US=> M{XXS3NCVkeHUh?=
HL-60 MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvwNmFxUUN3ME2yNE4xQTRzIN88US=> NEPZWpFUSU6JRWK=
Mo-T NF;tPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrkZ2ZyUUN3ME2yNE4yPjZ3IN88US=> MYTTRW5ITVJ?
NCI-H1355 M{TKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnMeIQ5UUN3ME2yNE4{Ozd2IN88US=> M2f0T3NCVkeHUh?=
HT-1080 MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzkflVKSzVyPUKwMlU1QTdizszN Ml:yV2FPT0WU
MIA-PaCa-2 M{Hnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;ER2lEPTB;MkCuOlg5OyEQvF2= MUPTRW5ITVJ?
NCI-H441 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PrTGlEPTB;MkCuO|M4QSEQvF2= NFTPXZRUSU6JRWK=
LCLC-97TM1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfHbYxKSzVyPUKwMlgyOzRizszN NYDxO3VDW0GQR1XS
HT-3 M3nxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJzLkW2N|Eh|ryP MYDTRW5ITVJ?
22RV1 MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD4TWM2OD1{MT61Olg2KM7:TR?= MV3TRW5ITVJ?
LK-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXTTWM2OD1{MT61PVU{KM7:TR?= NXe4TWZjW0GQR1XS
CW-2 M{fMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\yNWlEPTB;MkGuOlA3QSEQvF2= M{TlbnNCVkeHUh?=
KYSE-510 MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTTdllMUUN3ME2yNU43ODl3IN88US=> M1;jTHNCVkeHUh?=
CGTH-W-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJzLkexOlYh|ryP M1XzRXNCVkeHUh?=
NCI-H661 NFfJepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PEbmlEPTB;MkKuNFM1KM7:TR?= NF7iZoJUSU6JRWK=
KU-19-19 NWfyb|FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHuTmFOUUN3ME2yNk4yPjl5IN88US=> M3\6OnNCVkeHUh?=
NCI-H2122 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ{LkK0N|Ih|ryP NXHw[YZKW0GQR1XS
NCI-H526 M1LFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTzVXRKSzVyPUKyMlM5QTVizszN MnLpV2FPT0WU
NCI-H1650 M1n5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTiZ5JoUUN3ME2yNk44PjRizszN MWfTRW5ITVJ?
AM-38 NGnuVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITHeGJKSzVyPUKyMlg3QDlizszN NGLQTVJUSU6JRWK=
NCI-H2405 NF\sTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH62WnRKSzVyPUKzMlI2OzNizszN NWPCb3Y6W0GQR1XS
M14 NWTFdnNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PBW2lEPTB;MkOuOFA5QCEQvF2= MmfJV2FPT0WU
ES4 NU[2TIsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPJVI9DUUN3ME2yN{41OjN{IN88US=> M33PSXNCVkeHUh?=
DJM-1 NIrv[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrhTWM2OD1{Mz61NlM1KM7:TR?= MWHTRW5ITVJ?
S-117 MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:1elFlUUN3ME2yN{44PjVzIN88US=> MYjTRW5ITVJ?
MZ2-MEL M2nnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PQUWlEPTB;MkOuO|c2QSEQvF2= NIf4PZRUSU6JRWK=
SK-MEL-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLnT5pSUUN3ME2yN{45OTN|IN88US=> NHrpV49USU6JRWK=
HCC1806 M2LVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJ|Lki3NFkh|ryP M1LEdnNCVkeHUh?=
NMC-G1 M3LRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHpTWM2OD1{ND6yNlI3KM7:TR?= NGjSZmtUSU6JRWK=
DK-MG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHxRplKSzVyPUK0MlI6PCEQvF2= MXvTRW5ITVJ?
SK-N-FI NIC4fVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{KwUGlEPTB;MkSuN|MxOiEQvF2= MnnkV2FPT0WU
KINGS-1 NHv6OohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJ2LkS4O|Qh|ryP NIXBUmdUSU6JRWK=
HCC2998 NHLDOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\3TWM2OD1{ND60PFg2KM7:TR?= M1HVXnNCVkeHUh?=
ALL-PO M{XRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\0NG5KSzVyPUK0MlYyQSEQvF2= MUjTRW5ITVJ?
MPP-89 M1jaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu1RVZRUUN3ME2yOU4xPDV6IN88US=> NV3KOIJEW0GQR1XS
NCI-H2342 Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHtcoM3UUN3ME2yOU4yQTV|IN88US=> MUDTRW5ITVJ?
TE-1 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjLfmVKSzVyPUK1MlM2PjNizszN M{HyRXNCVkeHUh?=
RH-18 NXjM[ppiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXBfpU4UUN3ME2yOU42QTF6IN88US=> NFnuSXlUSU6JRWK=
HT-1376 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonlTWM2OD1{NT62OFY2KM7:TR?= NYL0PGJMW0GQR1XS
U-2-OS NVTLOY1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID3b3FKSzVyPUK1MlY5QDhizszN NHTkPYxUSU6JRWK=
BT-549 NX7Ye5ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T1S2lEPTB;MkWuPVAyOSEQvF2= NILKSFdUSU6JRWK=
NCI-H1755 M4q3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HCUWlEPTB;MkWuPVk1PSEQvF2= MnLDV2FPT0WU
EW-13 MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTKfXp1UUN3ME2yOk4xOjd2IN88US=> MX3TRW5ITVJ?
NB13 M1PiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnizTWM2OD1{Nj6wPVQ6KM7:TR?= NXjifI9mW0GQR1XS
NUGC-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLjTWM2OD1{Nj6yNVA{KM7:TR?= NVTST|ZkW0GQR1XS
GMS-10 NEfTb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDUflBKSzVyPUK2MlI{PTNizszN MV7TRW5ITVJ?
CHP-134 NGe4VXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITDVG1KSzVyPUK2MlM5PjdizszN M1i4TXNCVkeHUh?=
SW962 Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH5TopOUUN3ME2yOk42ODJzIN88US=> MUTTRW5ITVJ?
SNU-449 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2S3T2lEPTB;MkeuNFgxOyEQvF2= M{nRN3NCVkeHUh?=
HuP-T4 NX3hd4E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[3UZVyUUN3ME2yO{4xQDd7IN88US=> NVvBd4hbW0GQR1XS
SW948 NHX1VpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ5LkGzOFQh|ryP NYLudI03W0GQR1XS
NCI-H226 NWTkZVFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv6TWM2OD1{Nz60OVc5KM7:TR?= MnLjV2FPT0WU
SK-PN-DW MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPnTWM2OD1{Nz62NFEzKM7:TR?= NHHZ[o5USU6JRWK=
GI-1 NVW3dJpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7SXlBLUUN3ME2yO{44OjFizszN NETreodUSU6JRWK=
CAL-12T MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Did2lEPTB;MkiuNVEyOiEQvF2= MUTTRW5ITVJ?
YAPC M3;FOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL3c4dKSzVyPUK4MlI2PjRizszN MWnTRW5ITVJ?
SNU-C2B MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HOZmlEPTB;MkiuNlk3PCEQvF2= NIXiblVUSU6JRWK=
RCC10RGB MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm1dFdTUUN3ME2yPE42PDF5IN88US=> Ml71V2FPT0WU
ES7 M1\2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJ7LkG0OlUh|ryP NXnP[pNLW0GQR1XS
PANC-03-27 NVTkNJZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPYdGFUUUN3ME2yPU41PDRizszN M4PuNHNCVkeHUh?=
ES6 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\xTWM2OD1{OT64NVU4KM7:TR?= MkPEV2FPT0WU
HT-1197 M3TzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne3TWM2OD1|MD6wOVk5KM7:TR?= NGrZW5ZUSU6JRWK=
ZR-75-30 NYXJPYJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vKbWlEPTB;M{CuNlM5OyEQvF2= MUjTRW5ITVJ?
DB NFjGbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTvfWpKSzVyPUOwMlQ6PDJizszN MV3TRW5ITVJ?
OCI-AML2 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;rSoRUUUN3ME2zNU4xPjlizszN MW\TRW5ITVJ?
NCI-H2170 M2fFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LSdmlEPTB;M{GuPFUyPiEQvF2= Ml7ZV2FPT0WU
IST-MES1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7ENJJKSzVyPUOyMlI5QTdizszN MoW3V2FPT0WU
769-P MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3G2SGlEPTB;M{KuN|Y1OSEQvF2= M{PTenNCVkeHUh?=
COR-L23 NI\0ZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvLTWM2OD1|Mj65NFc{KM7:TR?= NX7HWJpiW0GQR1XS
SW626 M{fyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTN|LkG3O|Yh|ryP M{TSVHNCVkeHUh?=
LU-139 Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TrZmlEPTB;M{OuOlYxPSEQvF2= M2nZ[XNCVkeHUh?=
HT-144 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GxNGlEPTB;M{OuPFY{KM7:TR?= NVLHe5pnW0GQR1XS
CaR-1 MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN|Lkm4NlIh|ryP MX7TRW5ITVJ?
OE33 MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnHTWM2OD1|ND6yPFU2KM7:TR?= MUHTRW5ITVJ?
COLO-800 NIrjNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULmeY14UUN3ME2zOE4{PjR5IN88US=> MX\TRW5ITVJ?
NB14 NV;ne|FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTN2LkS2PFQh|ryP NUDGZ5NGW0GQR1XS
KURAMOCHI M3K1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK1TWM2OD1|Nj6xNVk5KM7:TR?= MlzSV2FPT0WU
SW48 M1LxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y0V2lEPTB;M{[uNlQ4PCEQvF2= M13DR3NCVkeHUh?=
Daoy Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTN4Lk[1N|gh|ryP MYrTRW5ITVJ?
TGBC24TKB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTlS4tKSzVyPUO2MlY4KM7:TR?= MkLuV2FPT0WU
DU-4475 MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3uxW2lEPTB;M{[uPVA{OyEQvF2= MXzTRW5ITVJ?
SW1417 NYrXWY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn3OpBpUUN3ME2zPE4xPTV{IN88US=> NXnlSJZUW0GQR1XS
EFO-21 NX\0epFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN6LkmzOFkh|ryP NX7CSm1VW0GQR1XS
MG-63 M{\wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILXV4hKSzVyPUO5MlM1OjRizszN MWXTRW5ITVJ?
LC-2-ad M1vSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonXTWM2OD1|OT61OVEzKM7:TR?= M3qwcHNCVkeHUh?=
NOMO-1 NGP0WoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\yW5pyUUN3ME2zPU45Ojd2IN88US=> MV7TRW5ITVJ?
COLO-741 MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTIWZdKSzVyPUSwMlE{ODRizszN NYTVfWxoW0GQR1XS
BxPC-3 MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjwd5RbUUN3ME20NE42Pjh4IN88US=> MUTTRW5ITVJ?
HSC-2 MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj6NJd7UUN3ME20NE46OTF|IN88US=> NVXoOHpsW0GQR1XS
UMC-11 M4LxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrBTWM2OD12MT6yOlMh|ryP NU[2OoVxW0GQR1XS
HCC1937 NUL5Z|ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTjS3pKSzVyPUSyMlc5PDNizszN NVP0boZtW0GQR1XS
Calu-6 M1\BOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj6OGJuUUN3ME20N{4zOzh{IN88US=> M2rLZ3NCVkeHUh?=
NCI-H1573 NYnwcldIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrte3pKSzVyPUSzMlM1PzdizszN NGfld|VUSU6JRWK=
SK-N-AS MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX1TWM2OD12Mz62NFE6KM7:TR?= NU\UcYliW0GQR1XS
PSN1 NX;KTmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXFTFBKSzVyPUS1MlI2PDhizszN MX7TRW5ITVJ?
TE-11 NFHJ[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq1eGI3UUN3ME20OU41QDR{IN88US=> MoTsV2FPT0WU
NCI-H1155 NYKyb21ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTR3Lki5Olch|ryP MV\TRW5ITVJ?
KM12 NYD3O4ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4izTWlEPTB;NEWuPVA4PiEQvF2= NYDXZ|U4W0GQR1XS
RO82-W-1 M1frXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTR4Lkm4NlIh|ryP M2\yUnNCVkeHUh?=
SW1573 NFXlcnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33DTmlEPTB;NEeuN|c{PiEQvF2= NIDX[WFUSU6JRWK=
CAKI-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLETWM2OD12OD6yPFQ2KM7:TR?= MojaV2FPT0WU
U-118-MG NVP5OHYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTR6LkO3NFIh|ryP NVzMWXV5W0GQR1XS
KYSE-520 NIT0VHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnFTWM2OD12OD60NFE3KM7:TR?= Mn\0V2FPT0WU
HT55 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7VUZhwUUN3ME20PU4yPDd2IN88US=> NUToWY5iW0GQR1XS
ChaGo-K-1 NUD4[IQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrWTWM2OD12OT60O|k{KM7:TR?= Mn7XV2FPT0WU
IA-LM MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHveo95UUN3ME21OE43OzJ{IN88US=> NGLhWWVUSU6JRWK=
UACC-62 Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvHTWM2OD13NT6xNFQ3KM7:TR?= MVPTRW5ITVJ?
MKN7 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTV4LkCyPFUh|ryP NELYV5VUSU6JRWK=
HPAF-II NU[3W2pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjETWM2OD13Nj60NFc{KM7:TR?= MXHTRW5ITVJ?
NTERA-S-cl-D1 NF3wfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTV5Lke3PEDPxE1? MXjTRW5ITVJ?
FTC-133 MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr0O5M6UUN3ME21PE4xQTZ7IN88US=> NFHHc2xUSU6JRWK=
MHH-ES-1 MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTV6LkS4NVQh|ryP MWfTRW5ITVJ?
JVM-2 NX[4VWx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTV6Lkm1NFYh|ryP M1iwfHNCVkeHUh?=
TCCSUP NU[2dFdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD5TWM2OD13OT61Nlc6KM7:TR?= NETXdW9USU6JRWK=
COLO-824 NFPwW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGC4VVhKSzVyPU[wMlA4OTlizszN MV3TRW5ITVJ?
647-V M2\JfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoGxTWM2OD14MD6xN|Q4KM7:TR?= NFTLN5hUSU6JRWK=
HD-MY-Z MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF71XXJKSzVyPU[wMlUzQTRizszN NVexV3BvW0GQR1XS
LS-411N NH3ZWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPpTWM2OD14MT6zPVA{KM7:TR?= M4ewSXNCVkeHUh?=
NCI-H596 NVLLPYNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHhTWM2OD14Mj63OFk3KM7:TR?= MVPTRW5ITVJ?
C-33-A MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjpTWM2OD14ND6wPVU4KM7:TR?= M4r0SHNCVkeHUh?=
BHY M2e3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon3TWM2OD14ND6xNlQ2KM7:TR?= NY\aZ5NLW0GQR1XS
KGN NGjlcmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PwN2lEPTB;NkSuOVUyPCEQvF2= M2TERnNCVkeHUh?=
NCI-H1092 NFjIRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTZ3LkCwPVUh|ryP NGjnVJFUSU6JRWK=
MZ1-PC NHvkVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUW1d|NXUUN3ME22OU42PjR7IN88US=> NH3Gdo9USU6JRWK=
LB831-BLC NFmxdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULoZnVsUUN3ME22OU45PDhzIN88US=> MY\TRW5ITVJ?
SW620 NVeweI9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvaTWM2OD14Nj6yNFM6KM7:TR?= NIfVNlNUSU6JRWK=
HuO-3N1 MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTZ6LkOyN|gh|ryP M2TPXXNCVkeHUh?=
SK-HEP-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nF[WlEPTB;NkmuPVQ5PiEQvF2= MV\TRW5ITVJ?
LCLC-103H NXfxeZRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTdyLk[3NFUh|ryP NX32dI9lW0GQR1XS
KYSE-70 MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXUTWM2OD15MD63PFM2KM7:TR?= MXPTRW5ITVJ?
Mewo MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\yU2lEPTB;N{GuOVA2KM7:TR?= MoTCV2FPT0WU
COLO-668 M2ixSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT6VIVKSzVyPUexMlg1PTFizszN MWTTRW5ITVJ?
NCI-H522 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLlTWM2OD15Mj6zOFE{KM7:TR?= MYLTRW5ITVJ?
NCI-H1437 NWrXcZJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHLc|ZKSzVyPUe0MlQxPDhizszN NWXhZVg3W0GQR1XS
U-266 NEjRS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\BeGxIUUN3ME23OU41PTF4IN88US=> MmXXV2FPT0WU
MC116 NVLhcoFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTd3LkW3NFgh|ryP MlPZV2FPT0WU
PANC-10-05 MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTd5LkSyOFMh|ryP MY\TRW5ITVJ?
KYSE-180 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXpc5BKSzVyPUe3MlU1PTRizszN MWPTRW5ITVJ?
JAR NXfTbGZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnqZ49bUUN3ME23PU4xPTR4IN88US=> NInmU4RUSU6JRWK=
CAL-62 M1qxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRThyLkC5OUDPxE1? NGryVWtUSU6JRWK=
A3-KAW NEPkfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTzTWM2OD16MD6yNVU1KM7:TR?= M3q3UnNCVkeHUh?=
PANC-08-13 MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXrV3pKSzVyPUixMlE4PjhizszN MXHTRW5ITVJ?
HSC-3 NX7FOmhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r4NGlEPTB;OEOuN|A4OSEQvF2= NIXvZWhUSU6JRWK=
HTC-C3 NWXxPHlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH4d41KSzVyPUizMlQ4ODJizszN M{GwTXNCVkeHUh?=
KY821 M33VR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHZTItkUUN3ME24OE4xQDl{IN88US=> M3v5c3NCVkeHUh?=
DoTc2-4510 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlruTWM2OD16ND6yNVg2KM7:TR?= M{CxUnNCVkeHUh?=
NCI-H1581 MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C4cmlEPTB;OEWuOFY1OSEQvF2= NGrhXoJUSU6JRWK=
KARPAS-299 NVjCb5ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPaTWM2OD16Nj6xPVc4KM7:TR?= M4ryUnNCVkeHUh?=
IST-MEL1 MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vVXWlEPTB;OE[uPFg4OiEQvF2= NEf0d2tUSU6JRWK=
KP-N-YS M{TPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTh7LkmwNlgh|ryP MVzTRW5ITVJ?
KYSE-410 NWS3cFgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHSb3J3UUN3ME25NU41ODR{IN88US=> M2DZZXNCVkeHUh?=
TE-10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M124bGlEPTB;OUGuOVYyOSEQvF2= MV\TRW5ITVJ?
SK-MEL-1 NIX6NnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjP[odKSzVyPUmyMlkyODZizszN MYTTRW5ITVJ?
COLO-792 Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTl3LkK1OlQh|ryP NYDlUI9oW0GQR1XS
SCH MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\QbWNnUUN3ME25Ok4{QDd5IN88US=> MlrZV2FPT0WU
NCI-H1792 NYjGPHZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki1TWM2OD17Nj64PVkzKM7:TR?= NY\wbIJnW0GQR1XS
NCI-H2029 Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj1VVBKSzVyPUm2Mlk2PjZizszN M2fL[3NCVkeHUh?=
SW684 NFrlXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTl6Lk[2OVQh|ryP MkS5V2FPT0WU
NCI-H209 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFyMD6xNlEh|ryP MV\TRW5ITVJ?
HLE MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn3[pBKSzVyPUGwOU4zQDJizszN NXv4bo5lW0GQR1XS
GOTO NYn2SGZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfKTWM2OD1zMEeuO|c4KM7:TR?= NHHxVVVUSU6JRWK=
NCI-H1793 NEDvbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvvXppGUUN3ME2xNFkvOjhizszN M3HZVHNCVkeHUh?=
D-392MG NFv6U5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK3eVcxUUN3ME2xNVcvOzl6IN88US=> NGL1b2NUSU6JRWK=
SW1990 M1uzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm4UmdKSzVyPUGyNE46PTFizszN MnXKV2FPT0WU
ML-2 M2[yUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTrOWRMUUN3ME2xNlEvPjd4IN88US=> NXHpOFdIW0GQR1XS
NCI-H2452 NHLMXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PwNGlEPTB;MUKyMlIyKM7:TR?= MkDzV2FPT0WU
SK-MEL-30 NUDJVY5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W2SmlEPTB;MUKzMlI1PCEQvF2= NWTnSZhyW0GQR1XS
SN12C NXTibXRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTF{ND6xO|Yh|ryP MknlV2FPT0WU
NCI-H1770 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF{NT61NVQh|ryP NEXwPGRUSU6JRWK=
SF268 NY\0enZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjSZndKSzVyPUGyOk4yPThizszN MofLV2FPT0WU
BALL-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\1cFdKSzVyPUGyOk4zOyEQvF2= M2fufXNCVkeHUh?=
COLO-679 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF{Nj63OVMh|ryP MmT2V2FPT0WU
A2780 NEjS[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XMSGlEPTB;MUK4Mlk5QCEQvF2= MYHTRW5ITVJ?
NCI-H1651 MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TuPGlEPTB;MUOxMlI1OyEQvF2= M1m4Z3NCVkeHUh?=
NCI-H2087 NGfN[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF|MT60PFMh|ryP M3fj[HNCVkeHUh?=
U-87-MG Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTF|Mz62NFQh|ryP NHO3WFdUSU6JRWK=
LB2518-MEL NWPtT49mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rzWWlEPTB;MUO1Mlk6OyEQvF2= NGLmNnFUSU6JRWK=
HCT-116 NY\JSIh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF|Nz6yNVch|ryP MmHqV2FPT0WU
Ca9-22 NF\uO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjudmFKSzVyPUGzPU45OzNizszN NVj2S3lMW0GQR1XS
COR-L88 NH;GO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MomwTWM2OD1zNEKuNVQh|ryP M1z1[HNCVkeHUh?=
CP50-MEL-B M3\4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zTSmlEPTB;MUS0MlUxOSEQvF2= NU\hWWFyW0GQR1XS
OVCAR-8 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrtTWM2OD1zNEWuOlM3KM7:TR?= NILWd3RUSU6JRWK=
SK-MEL-3 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLkTWM2OD1zNEeuPFc5KM7:TR?= NFLINmlUSU6JRWK=
GT3TKB NYDic|h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrTWnNKSzVyPUG0PU46OjhizszN NV7UdpFGW0GQR1XS
KYSE-450 M3faWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXCeYhqUUN3ME2xOVEvPTN7IN88US=> NGTjblBUSU6JRWK=
CAPAN-1 NH6wTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\KTWM2OD1zNUOuNFY1KM7:TR?= MVjTRW5ITVJ?
BEN NVXpNFlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELIcpFKSzVyPUG1N{46OjhizszN NX;zWIliW0GQR1XS
NCI-H1304 NVPDZWdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjwTWM2OD1zNUSuOlk1KM7:TR?= MlXSV2FPT0WU
KU812 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfyTWM2OD1zNUiuOlc1KM7:TR?= MmrOV2FPT0WU
Capan-2 MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13x[mlEPTB;MU[wMlU2OyEQvF2= MX7TRW5ITVJ?
A673 MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTF4MT63NFUh|ryP M331TnNCVkeHUh?=
SAS M{PCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fTS2lEPTB;MU[yMlY4QCEQvF2= MXzTRW5ITVJ?
NY M3OwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\GZoNKSzVyPUG2OU4{OTRizszN M2joUnNCVkeHUh?=
HCE-4 MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\UOpFzUUN3ME2xOlYvQDR3IN88US=> MXjTRW5ITVJ?
MDA-MB-231 NYfC[nplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF5Nz61NFMh|ryP MX3TRW5ITVJ?
no-10 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHL4S|dKSzVyPUG3PE4yOzRizszN M3qxcnNCVkeHUh?=
MZ7-mel NWnqbldlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnoTWM2OD1zN{iuOFY4KM7:TR?= MWXTRW5ITVJ?
NCI-H82 NGC3XZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PKTmlEPTB;MUiwMlE3PSEQvF2= M1iyXnNCVkeHUh?=
CAL-72 NGD3[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonuTWM2OD1zOEWuNFU1KM7:TR?= NXLPeG9oW0GQR1XS
NCI-SNU-5 NYm4VXE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF6Nj64OEDPxE1? Mn\4V2FPT0WU
OVCAR-4 M3XsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXLNVY4UUN3ME2xPFgvOzN|IN88US=> MX3TRW5ITVJ?
SCC-9 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLHTWM2OD1zOUGg{txO NIDnWXRUSU6JRWK=
KYSE-150 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[1TWM2OD1zOUGuPFg5KM7:TR?= MnztV2FPT0WU
HT-29 MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HwdGlEPTB;MkCxMlIyOiEQvF2= NHG1TGVUSU6JRWK=
COLO-678 NILGbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDpVG9KSzVyPUKwNU41PSEQvF2= NVq1VYg6W0GQR1XS
NCI-H650 M1Syfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[4b5FKSzVyPUKwNk4yODNizszN MWfTRW5ITVJ?
HuCCT1 NFTxU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zsSGlEPTB;MkC0MlIxQCEQvF2= NGXlfIZUSU6JRWK=
SW1116 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\xWGlEPTB;MkC3MlA4PyEQvF2= MVXTRW5ITVJ?
DBTRG-05MG NFi5bphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP5OlU6UUN3ME2yNFcvQTB7IN88US=> NIHYbmxUSU6JRWK=
SW982 NHHiTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HnWWlEPTB;MkC3Mlk1QCEQvF2= NIX2cHpUSU6JRWK=
RCM-1 NH;5eZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLOZYdKSzVyPUKxOE44PjJizszN Ml7ZV2FPT0WU
COLO-320-HSR MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPzOlRKSzVyPUKxOk4yOjVizszN M{PzOnNCVkeHUh?=
KNS-42 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\pemlEPTB;MkG2MlU4PCEQvF2= MkDnV2FPT0WU
C2BBe1 MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\1emdKSzVyPUKzNU46ODVizszN NFLFTlNUSU6JRWK=
CCRF-CEM NW\Nfpp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jJNWlEPTB;MkSzMlc6PSEQvF2= Moq3V2FPT0WU
SH-4 NHvHN|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDoTWM2OD1{NE[uNFkh|ryP MYPTRW5ITVJ?
LS-1034 M{LxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jpcmlEPTB;MkS2MlI3PiEQvF2= NXSyOXZHW0GQR1XS
NCI-H2347 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLpSYtKSzVyPUK0O{44OTNizszN NInFNGhUSU6JRWK=
RPMI-8866 NVLwXlFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\kSnJKSzVyPUK0PU4zPyEQvF2= M164bHNCVkeHUh?=
GAK M3vj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ3Mz6wNFIh|ryP M4[3O3NCVkeHUh?=
NB6 NHftZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3roPGlEPTB;MkewMlEh|ryP MWfTRW5ITVJ?
COLO-680N MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofnTWM2OD1{N{KuOVI4KM7:TR?= MlXpV2FPT0WU
RERF-LC-MS NEjvcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXwTWM2OD1{N{[uNFA4KM7:TR?= NFjxdYZUSU6JRWK=
TGBC11TKB MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYflS3ZPUUN3ME2yO|gvOTd6IN88US=> M3\1OnNCVkeHUh?=
C8166 NWftfWRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJ5OD61NFYh|ryP MVfTRW5ITVJ?
HDLM-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFqxXFZKSzVyPUK5OE41ODlizszN MUXTRW5ITVJ?
IGR-1 MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ7NT62OVkh|ryP NWnDRog6W0GQR1XS
FADU NFrpNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJ7Nz61NUDPxE1? Mn\lV2FPT0WU
L-428 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2WyZ2lEPTB;Mkm3MlYyPiEQvF2= NYKyfWFpW0GQR1XS
LU-65 MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfrTWM2OD1|MESuN|Ih|ryP Mo[5V2FPT0WU
HEL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTNyOT65PFMh|ryP M1O4dXNCVkeHUh?=
NCI-H810 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XmTWlEPTB;M{GwMlU4KM7:TR?= Mk\XV2FPT0WU
C3A M3X4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrF[Il{UUN3ME2zNVEvQDB{IN88US=> NFeySGhUSU6JRWK=
NCI-H630 M2\Pc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLUfItXUUN3ME2zN|IvOjl2IN88US=> MnmzV2FPT0WU
KP-N-YN NYj3eoxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;ZW5o4UUN3ME2zOFEvOTJ|IN88US=> NYD3cZQ5W0GQR1XS
MOLT-13 NHzrcm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvWTWM2OD1|NEKuN|I3KM7:TR?= MWXTRW5ITVJ?
NCI-H1993 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrhWI9mUUN3ME2zOFIvOzZ3IN88US=> NIC0WpBUSU6JRWK=
BE-13 NHz1O49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHniTJRKSzVyPUO0OE4yPjdizszN NF;p[mFUSU6JRWK=
IST-SL1 M{f6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP1TWM2OD1|NEeuOFAyKM7:TR?= MU\TRW5ITVJ?
TE-9 M3SzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD6TWM2OD1|NkOuOVg6KM7:TR?= NVz2OJdnW0GQR1XS
LU-135 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoP4TWM2OD1|NkeuNFM2KM7:TR?= NVfQeINzW0GQR1XS
T84 NHfHNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL2TWM2OD1|N{SuO|EzKM7:TR?= NHfZWotUSU6JRWK=
K-562 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTSTWM2OD1|OEOuN|Yh|ryP M1;oWXNCVkeHUh?=
SBC-5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17xZmlEPTB;M{i2Mlk5PSEQvF2= MUjTRW5ITVJ?
NB17 M1nIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjFcmFKSzVyPUO5Nk42QTZizszN NUnvS4dCW0GQR1XS
NCI-H2052 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTN7OD60O|Ih|ryP NHqw[oJUSU6JRWK=
HCC38 NWLlc|RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnmzTWM2OD12MEGuOVk{KM7:TR?= NUnEOJpGW0GQR1XS
NCI-H69 NHTROIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\zTWM2OD12NEGuNFg{KM7:TR?= MlXoV2FPT0WU

... Click to View More Cell Line Experimental Data
In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method: MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
15% Captisol		 17 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl
CAS No. 1032350-13-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • Answer:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • Question 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • Answer:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

selleck catalog

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products

  • Afuresertib (GSK2110183) New

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148 New

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79 New

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • AZD5363

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID